You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-1198-ESGO Post hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab

Article metrics

Article menu

Download PDFPDF

Translational research/biomarkers
2022-RA-1198-ESGO Post hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab
Free

 

Online download statistics by month:

Online download statistics by month: October 2022 to April 2024

AbstractFullPdf
Oct 20224005
Nov 20224606
Dec 20225509
Jan 20235707
Feb 20233907
Mar 20234304
Apr 20235105
May 20234204
Jun 20235004
Jul 20234109
Aug 20232405
Sep 20232207
Oct 20232603
Nov 20234307
Dec 20232406
Jan 20242706
Feb 20242806
Mar 20242202
Apr 20241804
Total6980106